Please provide your email address to receive an email when new articles are posted on . Real-world data show that only about 30% to 40% of patients with the most common cancers receive NGS testing.
Delays in time to first lenalidomide prescription fill for multiple myeloma. Preliminary results of a combined home and rural outpatient clinic-based infusion program through the Veterans Health ...
Phase 2 evaluation of the nilotinib-paclitaxel combination in patients with rare solid tumors: Rapid analysis and response evaluation of combination anti-neoplastic agents in rare tumors trial 1 (RARE ...
CEO Dr Ilian Iliev and Steve Cook, CEO of EMVC portfolio company DName-iT, talked with Proactive's Stephen Gunnion about ...
Life sciences and diagnostics company Revvity has had a busy couple of years, playing a major role in the next-generation sequencing-based screening of newborns to better enable healthcare ...
A new ultra-high-throughput sequencing platform boosts output, speeds turnaround, and improves genome coverage. It reduces costs, broadens clinical applications, and accelerates large-scale genomics ...
Like many cancer patients, Michael Wolff wanted answers. But, like many cancer patients in 2015, he wasn't getting them. After years of lymphoma treatment, the renowned jazz musician was still sick ...
The landscape of next-generation sequencing (NGS) continues to be defined by astonishing technological progress. We continue to witness sequencer throughput expansion with systems like the Illumina ...
Janina Krumbeck, PhD, discusses the clinical advantages of next-generation sequencing over traditional culture and how this untargeted diagnostic approach provides comprehensive pathogen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results